Biosimilar User Fee Talks Reach Starting Line As Report Shows Growing FDA Workload
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency staff efforts dedicated to 351(k) reviews increased more than 10-fold in fiscal year 2015, Eastern Research Group says.